Inflammatory bowel disease(IBD)is a chronic and recurrent disease of the gastrointestinal tract,mainly including Crohn's disease(CD)and ulcerative colitis(UC).However,current approaches against IBD do not precisely deliver drugs to the inflammatory site,which leads to life-long medication and serious side effects that can adversely impact patients'adherence.It is necessary to construct optimal drug delivery systems(DDSs)that can target drugs to the region of inflammation,thereby improve therapeutic effi-cacy and reduce side effects.With the burgeoning development of nanotechnology-based nanomedicines(NMs)and prodrug strategy,remarkable progresses in the treatment of IBD have been made in recent years.Herein,the latest advances are outlined at the intersection of IBD treatment and nanotherapeutics as well as prodrug therapy.First,the pathophysiological microenvironment of inflammatory sites of IBD is introduced in order to rationally design potential NMs and prodrugs.Second,the necessity of NMs for the IBD therapy is elaborated,and the representative nanotherapeutics via passive targeted and ac-tive targeted NMs developed to treat the IBD are overviewed.Furthermore,the emerging prodrug-based therapeutics are summarized,including 5-aminosalicylic acid-,amino acid-,and carbohydrate-conjugated prodrugs.Finally,the design considerations and perspectives of these NMs and prodrugs-driven IBD ther-apeutics in the clinical translation are spotlighted.

Mengchi Sun;Weiyue Ban;Hao Ling;Xiang Yu;Zhonggui He;Qikun Jiang;Jin Sun

Wuya College of Innovation,Shenyang Pharmaceutical University,Shenyang 110016,China;Huzhou Central Hospital,Affiliated Huzhou Hospital,Zhejiang University School of Medicine,Affiliated Central Hospital Huzhou University,Huzhou 110016,China

中国化学快报（英文版）

[1]Mengchi Sun;Weiyue Ban;Hao Ling;Xiang Yu;Zhonggui He;Qikun Jiang;Jin Sun-.Emerging nanomedicine and prodrug delivery strategies for the treatment of inflammatory bowel disease)[J].中国化学快报（英文版）,2022(10):4449-4460

DDSs,apeutics,spotlighted

Emerging,delivery,strategies,treatment,inflammatory,bowel,disease,Inflammatory,IBD,chronic,recurrent,gastrointestinal,tract,mainly,including,Crohn,CD,ulcerative,colitis,UC,However,approaches,against,do,precisely,which,leads,life,long,medication,serious,effects,that,can,adversely,impact,patients,adherence,It,necessary,construct,optimal,systems,region,inflammation,thereby,improve,effi,cacy,reduce,With,burgeoning,development,nanotechnology,nanomedicines,NMs,strategy,remarkable,progresses,have,been,made,recent,years,Herein,latest,advances,are,outlined,intersection,nanotherapeutics,well,therapy,First,pathophysiological,microenvironment,sites,introduced,order,rationally,design,potential,prodrugs,Second,necessity,elaborated,representative,via,passive,targeted,developed,overviewed,Furthermore,emerging,summarized,aminosalicylic,acid,carbohydrate,conjugated,Finally,considerations,perspectives,these,driven,clinical,translation

0.533677